Results. The proportion of AIDS-related deaths decreased markedly between 1995 and 2017, while the proportion of deaths from non-AIDS cancers has increased (figure). Patients with non-AIDS cancers were older, had a higher CD4 count and greater proportion with undetectable viral load, and were more likely to be male; over 80% were current or prior smokers (table) . Among all deaths from 2013 to 2017, 44% of eligible patients received colon cancer screening, 66% received cervical cancer screening, and 29% received breast cancer screening. Of patients who died from HCC, one out of six had imaging for HCC within 1 year and none within 6 months of diagnosis.
*Median (IQR) or n (%). ‡ Most common: HCC (6), head/neck (4), prostate (3).
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Primary Central Nervous System Lymphoma in Patients with HIV and Non-HIV: Should We Treat Them Differently? Dima Dandachi, MD
Background. Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma, mostly diffuse large B-cell type. In patients living with HIV (PLWH), PCNSL is associated with Epstein-Barr virus. The optimal diagnostic and prognostic tools, and treatment are yet to be defined. PLWH are typically excluded from prospective studies. The management of PCNSL is adopted from immunocompetent patients.
Methods. We retrospectively reviewed 122 PCNSL cases presenting to MD Anderson Cancer Center from 2000 to 2016 (n = 84) and Ben-Taub Hospital from 2012 to 2016 (n = 38) to evaluate and compare the clinical characteristics, management, and clinical outcomes in patients with or without HIV infection.
Results. Among 122 PCNSL cases, 21% had positive HIV test, of those, 89% had CD4 < 200 and 77% were not on antiretrovirals and not virally suppressed. PLWH were significantly younger (37 vs. 62 years. P < 0.01), and more likely to be African-Americans (61% vs. 7%; P < 0.01) and males (73% vs. 50%; P = 0.04) than non-HIV patients. There were no differences in presenting symptoms, ocular involvement, B-symptoms, and deep brain involvement. PLWH were more likely to have multiple brain lesions (69% vs. 44%, P = 0.02). Immunohistochemistry prognostic markers and the International Extranodal Lymphoma Study Group (IELSG) prognostic score were not different between HIV and non-HIV patients. Nevertheless, treatment strategies varied significantly. PLWH were more likely to receive whole brain radiation therapy as sole treatment (65% vs. 4%) and palliative care (12% vs. 2%), and less likely to receive chemotherapy (23% vs. 94%) (P < 0.01). Also, 13% of the patients (all non-HIV) underwent autologous stem cell transplant. Most PLWH (88%) started antiretroviral therapy after diagnosis. Higher IELSG score was an independent predictor of mortality in multivariate regression analysis. The 2-year survival did not differ between PLWH and non-HIV patients [46% (30-72%) vs. 61% (52-72%) (P = 0.12)].
Conclusion. Variation in the treatment of PCNSL between HIV and non-HIV patients is not fully explained by baseline characteristics and prognostic factors. More efforts are needed to identify causes underlying these disparities and ways to alleviate them.
Disclosures. Background. Although cervical cancer disproportionately affects women living with HIV, achieving high cervical cancer screening rates for this population continues to be a challenge. In our urban HIV clinic caring for ~700 women, the baseline annual on-site screening rate was only 68% in 2017. The goal of this study was to identify factors related to low rates of screening in order to inform quality improvement efforts.
Methods. Over the time period of January 1, 2015 and June 30, 2017, we conducted a retrospective chart review of 185 randomly selected women with HIV. We collected data on cervical cancer screening adherence according to the screening guidelines provided by the Department of Health and Human Services. Correlations between clinical and demographic factors and patterns of cervical cancer screening were analyzed using chi square and logistic regression.
Results. During the review period, 68 (37%) patients completed two annual cervical cancer screenings, 96 (52%) completed 1, and 21 (11%) completed none. Of those completed, 22% were abnormal. When follow-up colposcopy was indicated, 18 of 42 (42%) women completed colposcopy within 6 months. Patients with screening rates lower than recommended were more likely to have substance use disorders and be uninsured (P < 0.05). Factors significantly associated with adherence to screening guidelines included history of an abnormal pap test, current antiretroviral therapy, and more than four HIV-related primary care visits per year. Age and HIV viral load between the groups were not significantly different.
Conclusion. In this urban HIV clinic cohort, a high proportion of women completed at least one cervical cancer screening test over a 2-year period, a promising result in the setting of a recent change in cervical cancer screening guidelines recommending less frequent testing. However, a smaller proportion completed colposcopy when indicated. The strongest predictors of low adherence to the guidelines were substance use disorder and lack of insurance. The next phase of this project will include a review of cervical and anal cancer screening rates among women, as well as patient surveys to determine quality improvement strategies that may further enhance acceptability and access to cervical and anal cancer screening and prevention.
Disclosures. All authors: No reported disclosures. Background. Although antiretroviral therapy (ART) has resulted in a marked decrease in AIDS-related morbidity and mortality, the therapeutic benefit is often limited by side effects such as metabolic derangement, lipodystrophy, hyperlipidemia and cardiovascular diseases. The underlying mechanisms of these toxicities are not well understood. With a high prevalence of metabolic syndrome, we investigated the effect of ART on cholesterol biosynthesis.
Antiretrovirals Perturb Cholesterol Biosynthesis in
Methods. A case-control study of ART-induced toxicity was conducted. Cases comprised HIV-infected individuals (N = 16) on ART with viral loads averaging 20 copies/mL. Cases were matched to HIV-uninfected controls (N = 16) by age, sex, and race/ethnicity. RNA was isolated from PBMCs after which qRT-PCR was performed. Wilcoxon Rank Test was used to evaluate significance (P < 0.05). The cholesterol regulation genes that were studied include: sterol regulatory element-binding protein 2 (SREBP2, sensory control), HMG CoA reductase (HMGCR, de novo synthesis), low density lipoprotein receptor (LDLR, uptake) and ATP-binding cassette transporter member 1 (ABCA1, efflux), AMP-activated protein kinase A1and B2 (AMPKA1 and AMPKB2, markers of cellular energy status) as well as NR1H3 (also known as LXRα-liver x receptor alpha, a precursor to ABCA1).
Results. The age of participants ranged from 33 to 66 years; 69% males and 31% females. The ethnicity comprised of 25% Non Hispanic whites, 6% Hispanic white and 69% African Americans. The ART regimen of the cohort was mostly tenofovir/emtricitabine (44%), tenofovir/emtricitabine/efavirenz (19%) and zidovudine/lamivudine (6%). ABCA1 and HMGCR were upregulated in cases compared with healthy controls (P < 0.01 and P = 0.01, respectively) (Figure 1) .
Conclusion. ART might cause intracellular accumulation of cholesterol leading to upregulation of efflux gene, ABCA1. Perturbation of cholesterol biosynthesis may be in the causal pathway of ART-associated metabolic syndrome.
Disclosures. All authors:
No reported disclosures. Background. Tenofovir alafenamide (TAF) was approved in 2015 for use in HIV-1. TAF decreases risk of renal and bone toxicity compared with tenofovir disproxil fumarate (TDF). Early clinical trials reported median increases in low-density lipoprotein (LDL) of 20-29 and 9-13 mg/dL for total cholesterol (TC) following switch therapy from TDF-containing regimens at 48 weeks, raising concern for increased cardiovascular (CVD) risk over time. We assessed real-world changes in serum lipid concentrations following transition to TAF-containing regimens.
Changes in Lipid Profiles
Methods. Eligible subjects in the U.S. Military Natural History Study, a longitudinal cohort of HIV-infected military beneficiaries, had been switched from TDF to TAF-based regimens, and had pre-and post-switch lipid profiles available. Antiretroviral therapy history, serum lipids, CD4 count and viral load were collected from the study database. Wilcoxon rank-sum test was used to compare lipid profile changes.
Results. As of January 1, 2018, 408 subjects on TDF switched to TAF; 238 had pre and post lipid profiles. Subjects were primarily male (95%), 45.4% African American, 70% were ≥40 years old at TAF start; 8% had CVD and 10% had diabetes. Changes in lipid profiles and CD4 count are presented in Table 1 . No difference was seen when categorized by gender, race, or age. Lipid changes were not seen in subjects switched from an efavirenz (EFV) regimen. Increases in TC, HDL, and LDL were observed in those switched from rilpivirine (RPV) (P = 0.002, P = 0.0404, and P = 0.0296) or elvitegravir (EVG) (P < 0.0001, P = 0.0003, P = 0.0040) regimens.
Conclusion. We found significant changes in serum lipids, albeit lower than median changes observed in licensing trials. Changes were not observed in those switching from EFV, contrasting with those switching from RPV or EVG. Background. As HIV-infected patients are living longer due to ART and decreasing mortality, the burden of noncommunicable diseases (NCDs) is expected to rise. With the implication of Insulin resistance (IR) and inflammation in the pathogenesis of Diabetes Mellitus (DM), DM is likely to be increasing in the HIV-infected patients in the Sub-Saharan Africa (SSA). HIV is characterized with systemic inflammation and markers which quickly decrease with ART initiation regardless of type of ARV regimen though they do not normalize. We thus assessed the relationship between IR and Virologic treatment failure among HIV-1-infected individuals at 12 months of first-line ART in the Zambian ART program.
Methods. We conducted a cross-sectional survey among HIV-1-infected individuals at 12 months (±3 months) of first-line ART. Systematic sampling was performed and 20 clinics were selected based on the random starting-point, sampling interval and cumulative population size giving a sample size of 460. Eligible patients had their fasting blood specimens collected for VL, insulin, blood glucose, high sensitive c-reactive protein (hsCRP), tumour necrosis factor alfa (TNFa) and Lipogram. Anthropometric indices were also measured including visceral fat. Insulin resistance (IR) was determined using Homeostatic model assessment (HOMA). Proportions for each outcome at linearized standard error 95% confidence interval and summary estimates were determined. Viral Load suppression (VLS) was defined according to the detection threshold which was <20 copies/mL and treatment failure was defined as VL > 1,000 copies/mL.
Results. Of the 473 patients enrolled, 142 (30%): 95% CI (26%, 34%) had IR. 19% of Individuals with IR had treatment failure compared with 5.7% with treatment failure and without IR (P-value < 0.0001). Treatment success was associated with less likelihood of IR (OR 0.26 (0.14, 0.48), P-value < 0.0001. Among individuals with VLS, 82, out of 142 (58%) 95% CI (0.54%, 0.70%) had IR compared with 232 out of 331, (70%) 95% CI (65%, 75%) who did not have IR (P-value = 0.042) Conclusion. Patients with poor virological outcomes at 12 months of first-line ART had increased likelihood of insulin resistance compared with those with treatment success. There was good evidence to suggest that the proportion of those with VLS and IR was less than those with VLS and no IR.
Disclosures. All authors: No reported disclosures.
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